Golidocitinib
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Golidocitinib
- DrugBank Accession Number
- DB18057
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 489.584
Monoisotopic: 489.260071274 - Chemical Formula
- C25H31N9O2
- Synonyms
- (.alpha.r)-n-(3-(2-((3-methoxy-1-methyl-1h-pyrazol-4-yl)amino)-4-pyrimidinyl)-1h-indol-7-yl)-.alpha.,4-dimethyl-1-piperazineacetamide
- 1-piperazineacetamide, n-(3-(2-((3-methoxy-1-methyl-1h-pyrazol-4-yl)amino)-4-pyrimidinyl)-1h-indol-7-yl)-.alpha.,4-dimethyl-, (.alpha.r)-
- External IDs
- AZD 4205
- AZD-4205
- AZD4205
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Golidocitinib hemi-ethyl acetate solvate NS94P621A0 2091135-65-6 Not applicable
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 3BY9Z3M34G
- CAS number
- 2091134-68-6
- InChI Key
- CVCVOSPZEVINRM-MRXNPFEDSA-N
- InChI
- InChI=1S/C25H31N9O2/c1-16(34-12-10-32(2)11-13-34)23(35)28-20-7-5-6-17-18(14-27-22(17)20)19-8-9-26-25(29-19)30-21-15-33(3)31-24(21)36-4/h5-9,14-16,27H,10-13H2,1-4H3,(H,28,35)(H,26,29,30)/t16-/m1/s1
- IUPAC Name
- (2R)-N-(3-{2-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide
- SMILES
- COC1=NN(C)C=C1NC1=NC=CC(=N1)C1=CNC2=C(NC(=O)[C@@H](C)N3CCN(C)CC3)C=CC=C12
References
- General References
- Not Available
- External Links
- ChemSpider
- 71117616
- ChEMBL
- CHEMBL4577523
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Refractory Peripheral T-Cell Lymphoma / Relapsed or Refractory Peripheral T-cell Lymphoma / Relapsed Peripheral T-Cell Lymphoma 1 2 Not Yet Recruiting Treatment Non-Small Cell Lung Cancer (NSCLC) 1 2 Recruiting Treatment Non-Small Cell Lung Cancer (NSCLC) 1 2 Recruiting Treatment Peripheral T-Cell Lymphoma (PTCL) 1 1 Completed Other Healthy Volunteers (HV) 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 2.44 Chemaxon pKa (Strongest Acidic) 8.99 Chemaxon pKa (Strongest Basic) 7.8 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 116.23 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 151.52 m3·mol-1 Chemaxon Polarizability 53.23 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at September 08, 2023 20:25 / Updated at September 28, 2023 05:47